MedTrace Logo

Immune Spatial Features of Guselkumab Cutaneous Response

NCT05858632 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-08-28

No results posted yet for this study

Summary

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Conditions

  • Psoriasis of Scalp

Interventions

DRUG

Guselkumab

Guselkumab treatment for \~ 9 months

Sponsors & Collaborators

Principal Investigators

  • Raymond Cho, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858632 on ClinicalTrials.gov